GELS

MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company's proprietary gel-based delivery platform.

MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world's fastest-growing pharmaceutical and biotechnology ecosystems.

MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq's planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.

2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market LAS VEGAS, NV / ACCESS Newswire / May 14, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported record results for the first quarter ended March 31, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.

MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities. Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and ramping up commercialization of its nutraceutical products.

2025 Non-GAAP Net Income Totaled $162,000 or $0.02 Per Share Record Results Driven by Fifth Sequential Quarter of Record-Setting Revenues, with the Momentum Setting Stage for Another Year of Double-Digit Growth LAS VEGAS, NV / ACCESS Newswire / April 8, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported audited results for the year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.